Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

ERC Advanced Grants for Hannah Monyer and Michael Platten

No. 20 | 11/04/2024 | by Koh

The European Research Council (ERC) supports visionary, ground-breaking research projects with its "Advanced Grants". This year, the Council awarded the prestigious funding to two researchers at the German Cancer Research Center (DKFZ): Neuroscientist Hannah Monyer, DKFZ and Heidelberg University Hospital, wants to find new explanations for the development of neurodegenerative diseases. Neurologist Michael Platten, DKFZ and University Medical Center Mannheim, will use the ERC funding to develop and test personalized cellular immunotherapies against malignant brain tumors.

Hannah Monyer
© Schwerdt / Universität Heidelberg

The European Research Council promotes basic research in order to advance particularly forward-looking projects and open up new interdisciplinary fields of knowledge. Each year, the Council announces "ERC Advanced Grants" for outstanding researchers in Europe, which are awarded in a highly competitive process. This year, two DKFZ researchers, Hannah Monyer and Michael Platten, have been awarded the particularly prestigious ERC grants.

New approach to the treatment of neurodegenerative diseases

The hippocampus is an area of the cerebrum in which new memory is created. The activity of the hippocampus is controlled by a small region of the brain known as the septum. Certain inhibitory neurons of the septum are considered "pacemaker cells": they extend into the structures of the hippocampus, where they synchronize the activity of neuronal ensembles and enable cognitive performance.

Hannah Monyer has evidence that the septal neurons are associated with the development of neurodegenerative diseases. If these neurons are damaged, spatial and episodic memory (i.e. what, when, where) are impaired. In various animal models of neurodegenerative diseases, an increased sensitivity of the septal neurons has been observed. They are considered to be very susceptible to disturbance because they fire at a high rate and are therefore extremely hungry for energy. There are hints that damage to the energy-producing mitochondria is responsible for this susceptibility.

In her project, funded by the ERC with two million euros over four years, Monyer wants to investigate how a loss of function of the septal neurons affects memory formation in the downstream hippocampus and which cellular mechanisms are underlying this. What makes the septal neurons so vulnerable? Is it really mitochondrial defects? Monyer and her team want to find out what role these special neurons play in the symptoms in the early stages of neurodegenerative diseases and whether they could therefore represent a potential new target for therapeutic interventions.

Hannah Monyer heads the Clinical Neurobiology Division, which is based at both the DKFZ and Heidelberg University Hospital. The neuroscientist has already received numerous awards, including the Leibniz Prize in 2004. In 1999, she received the Order of Merit of the Federal Republic of Germany. The ERC had already awarded her an Advanced Grant in 2010.

Michael Platten
© FGV-Medienzentrum, Med. Fakultät Mannheim

Personalized cellular immunotherapies against malignant brain tumors

Malignant brain tumors are usually incurable diseases that often cannot be completely removed surgically. Cellular immunotherapies that specifically target such brain tumors could be a promising treatment alternative. Michael Platten wants to use artificial intelligence to advance personalized cellular immunotherapies against malignant brain tumours in a project funded by the ERC with 2.5 million euros over five years.

Platten and his team recently invented an innovative approach for the development of cellular immunotherapies: They first isolate T cells from patients' tumor tissue - without knowing the specificity of their T cell receptors. An AI model trained on the genetic sequence data of these T cells can predict which T cell receptors recognize the cancer. This classifier, called "predicTCR ", identifies tumor-reactive T cells with an accuracy of over 90 percent.

The researchers now want to use predicTCR to investigate the genetic programs of tumor-reactive T cells isolated from brain tumors and use these programs to improve the anti-tumor activity of the immune cells.

To obtain therapeutic T cells, the genes of T cell receptors with strong activity against glioblastoma cells must be isolated and transferred to donor T cells. The resulting T-cell receptor transgenic T-cells will then be further tested and prepared for clinical application.

Michael Platten heads the Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology and is spokesperson for the Research Program Immunology, Infection and Cancer at the DKFZ and Medical Director of the Neurological University Hospital Mannheim. Among numerous other awards, he was honored with the German Cancer Prize in 2019.

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS